Salix Pharmaceuticals (NASDAQ:SLXP) is a step closer to bringing to the U.S. Food and Drug Administration a once-a-day pill version of injectable constipation drug Relistor. Relistor is indicated for ...

Salix, which specializes in gastrointestinal treatments, could pay Progenics another $90 million if the company reaches certain regulatory milestones in the United States. Salix will fund development, ...

Progenics Pharmaceuticals announced that it will hand over commercial duties on Relistor, a subcutaneous injection for opioid-induced constipation (OIC), to Salix, beginning in April. Financial terms ...

The companies are looking to get Relistor approved for the treatment of opioid-induced constipation (:OIC) in patients taking opioids for chronic non-cancer pain. Relistor is a peripherally acting ...

Relistor approved for OIC Salix and Progenics announced that the Food and Drug Administration (FDA) has approved Relistor (methylnaltrexone) subcutaneous injection for the treatment of opioid-induced ...

With oral Relistor's approval, Valeant just got a new weapon in its battle with AstraZeneca for the opioid-induced constipation throne. Can that weapon reach the billion-dollar sales benchmark quoted ...

Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...

Please provide your email address to receive an email when new articles are posted on . A single dose of Relistor injection produced rescue-free laxation in severely ill patients with opioid-induced ...

Data from a Post-Hoc Analysis Supports the Use of Salix's RELISTOR for Patients with Opioid-Induced Constipation and Advanced Illness in the Emergency Department Setting LAVAL, QC, Dec. 22, 2021 ...

TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced it has extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to continue Wyeth’s ...

Valeant and Progenics announced that the Food and Drug Administration (FDA) has approved Relistor (methylnaltrexone bromide) tablets for the treatment of opioid-induced constipation (OIC) in adults ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Health Canada and ...